Financial Daily from THE HINDU group of publications
Tuesday, Mar 09, 2004
Financial Daily from THE HINDU group of publications Tuesday, Mar 09, 2004 |
||
|
|
||
|
Marketing
-
New Products & Services Industry & Economy - Health Natco launches another anti-cancer drug Our Bureau
Hyderabad , March 8 NATCO Pharma Ltd (NPL) has announced the launch of yet another anti-cancer drug from its stable. The company has been tapping this segment with low-cost drugs. In a press release here on Monday, the company said it has launched Geftinib 250 mg tablets under the brand name `Geftinat.' This is a first time introduction of the generic version of Geftinib in the country, it said. Geftinib is a selective epidermal growth factor receptor. Natco's Geftinat aims at presenting a remedy for lung cancer. It is an effective monotherapy treatment for patients suffering from non-small cell lung cancer, the release said. Priced at Rs 325 per tablet of 250 mg, which is said to be one-tenth of the cost of international brand presently available in the market, the company claimed that the drug was invented and patent application was filed prior to 1995. Keeping in view the slated future launches, the company expects to catapult itself into a significant position in the oncology segment, the release said.
More Stories on : New Products & Services | Health | Pharmaceuticals
Article E-Mail :: Comment :: Syndication :: Printer Friendly Page
|
Stories in this Section |
|
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription Group Sites: The Hindu | Business Line | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |
Copyright © 2004, The
Hindu Business Line. Republication or redissemination of the contents of
this screen are expressly prohibited without the written consent of
The Hindu Business Line
|